Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel method for differentiation between Trastuzumab and host adaptive response.

Molecular immunology - 1 Sept 2011

Denisova Galina, Jenkins Kristina, Evelegh Carole, Bramson Jonathan

Abstract excerpt

Humoral immune response to human epidermal growth factor receptor 2 (HER-2/neu or ErbB-2) has been detected in sera of breast cancer patients and shown to be an appropriate prognostic marker (Taylor et al., 2007). However, since Trastuzumab (Herceptin) is a widely used monoclonal antibody as cancer therapy agent for tumors over-expressing HER-2, there is a need for an efficient way to detect host-generated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptive Immunity
Share to Antibodies, Monoclonal, Humanized
Share to Antibody Affinity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Autoantibodies

Share to Autoantigens

Share to Hematologic Tests

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Identifiers

PMID: 21645926
DOI: 10.1016/j.molimm.2011.05.016

Genes

ECD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Novel method for differentiation between Trastuzumab and host adaptive response.PMID 21645926Read ↗

A Genetically Encoded Endogenous Antibody Recruitment Strategy for Innate Immune‐Mediated Killing of Cancer CellsSemantic proximity Read ↗

Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.Semantic proximity Read ↗

Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic MiceSemantic proximity Read ↗

A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2.Semantic proximity Read ↗

Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.Semantic proximity Read ↗

Human ErbB-2 (Her-2) Transgenic Mice: A Model System for Testing Her-2 Based VaccinesSemantic proximity Read ↗

Levels of Specific Peptide-HLA Class I Complex Predicts Tumor Cell Susceptibility to CTL KillingSemantic proximity Read ↗

Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity.Semantic proximity Read ↗

Protection against mammary tumor growth by vaccination with full-length, modified humanErbB-2 DNASemantic proximity Read ↗

A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric ProteinsSemantic proximity Read ↗

A lysine-free mutant of epidermal growth factor as targeting moiety of a targeted toxin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.